Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Wolff D, et al. Among authors: perez simon ja. N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. N Engl J Med. 2024. PMID: 39292927 Clinical Trial.
Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C, Solano C, Ferrá C, Sampol A, Valcárcel D, Pérez-Simón JA; Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular). Martínez C, et al. Biol Blood Marrow Transplant. 2009 May;15(5):639-42. doi: 10.1016/j.bbmt.2009.01.014. Epub 2009 Mar 9. Biol Blood Marrow Transplant. 2009. PMID: 19361757 Free article. Clinical Trial.
The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D. Perez-Simón JA, et al. Haematologica. 2013 Apr;98(4):526-32. doi: 10.3324/haematol.2012.065599. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065527 Free PMC article. Clinical Trial.
Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
Martínez-Bravo MJ, Calderón-Cabrera C, Márquez-Malaver FJ, Rodríguez N, Guijarro M, Espigado I, Núñez-Roldán A, Pérez-Simón JA, Aguilera I. Martínez-Bravo MJ, et al. Biol Blood Marrow Transplant. 2014 Sep;20(9):1356-62. doi: 10.1016/j.bbmt.2014.05.008. Epub 2014 May 17. Biol Blood Marrow Transplant. 2014. PMID: 24844856 Free article.
Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sánchez-Guijo F, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19. Biol Blood Marrow Transplant. 2014. PMID: 24952358 Free article. Clinical Trial.
Human Bone Marrow Stromal Cells Differentiate Into Corneal Tissue and Prevent Ocular Graft-Versus-Host Disease in Mice.
Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, Herrero C, Velasco A, Carrancio S, Caballero-Velázquez T, Rodríguez-Barbosa JI, Parrilla M, Del Cañizo C, San Miguel J, Aijón J, Pérez-Simón JA. Sánchez-Abarca LI, et al. Cell Transplant. 2015;24(12):2423-33. doi: 10.3727/096368915X687480. Epub 2015 Feb 18. Cell Transplant. 2015. PMID: 25695936 Free article.
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA. López-Corral L, et al. Biol Blood Marrow Transplant. 2019 Sep;25(9):1703-1712. doi: 10.1016/j.bbmt.2019.04.026. Epub 2019 May 3. Biol Blood Marrow Transplant. 2019. PMID: 31054983 Free article. Clinical Trial.
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.
Caballero-Velázquez T, Calderón-Cabrera C, López-Corral L, Puig N, Marquez-Malaver F, Pérez-López E, García-Calderón C, Rosso-Fernández CM, Caballero Barrigón D, Martín J, Mateos MV, San Miguel J, Pérez-Simón JA; European Myeloma Network. Caballero-Velázquez T, et al. Bone Marrow Transplant. 2020 Feb;55(2):419-430. doi: 10.1038/s41409-019-0670-6. Epub 2019 Sep 24. Bone Marrow Transplant. 2020. PMID: 31551517 Clinical Trial.
Polyphenolic Extract (PE) from Olive Oil Exerts a Potent Immunomodulatory Effect and Prevents Graft-versus-Host Disease in a Mouse Model.
Alvarez-Laderas I, Ramos TL, Medrano M, Caracuel-García R, Barbado MV, Sánchez-Hidalgo M, Zamora R, Alarcón-de-la-Lastra C, Hidalgo FJ, Piruat JI, Caballero-Velázquez T, Pérez-Simón JA. Alvarez-Laderas I, et al. Biol Blood Marrow Transplant. 2020 Apr;26(4):615-624. doi: 10.1016/j.bbmt.2019.11.019. Epub 2019 Nov 19. Biol Blood Marrow Transplant. 2020. PMID: 31756538 Free article.
293 results